pharmafocus_june_2018_cover

The June 2018 issue of Pharmafocus is now live!

pharmafile | May 31, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Ebola, GDPR, Trump, UK, brexit, data managment, market access, pharma 

The new June edition of Pharmafocus is now available to read online.

Following the much-publicised devastation it wrought in 2013 to 2016, the threat of Ebola is looming again, this time in the Democratic Republic of Congo in Central Africa. The WHO has authorised the use of experimental vaccine V920, with manufacturer MSD committing to provide more than 10,000 doses of the preventative therapy to the region. You can read the full story on our front page.

After more than a year of threats, President Trump’s action plan for cracking down on the pharmaceutical industry’s oftentimes predatory pricing practices, but the pledges have been found by some to be underwhelming – find out why on page 7.

In the UK, the news of Prime Minister Theresa May’s commitment to the use of AI to accelerate cancer diagnosis times and relieve the underfunded NHS comes as a step in the right direction, but how far will that commitment stretch in terms of actual funding? Find out the details on page 4.

And with the issue of data being a hot topic following the Facebook/Cambridge Analytica scandal and the advent of GDPR in Europe, don’t miss our in-depth feature on data management in the clinical space on page 22, or our special Market Access feature on the impact of Brexit on page 17.

Read the June edition of Pharmafocus online now!

Related Content

Geneos Therapeutics shares data from phase 1/2 trial for cancer vaccine

Geneos Therapeutics has announced that it has published positive safety, immunogenicity and efficacy data from …

Curve Therapeutics’ CSO publishes research on HIF inhibition for cancer treatment

Curve Therapeutics has announced that its chief scientific officer, Professor Ali Tavassoli has published research …

Verastem Oncology gains Fast Track Designation for combination NSCLC treatment

Verastem Oncology has announced that the US Food and Drug Administration (FDA) has granted Fast …

Latest content